Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials

Clinical Nutrition

Volumn 34, Issue 5, 2015, Pages 838-844

  Ding, Yi ^a   Li, YuWen ^a   Wen, AiDong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinical trial; Meta analysis; Niacin; Type 2 diabetes

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; BLOOD; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; FACTUAL DATABASE; META ANALYSIS; METABOLISM; RISK ASSESSMENT;

BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 84939265157     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.09.019     Document Type: Article

References (34)

1. Basevi V., Di Mario S., Morciano C., Nonino F., Magrini N. Comment on: American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl. 1):S11-S61. Diabetes Care. 2011, 34, e53; author reply e54.
2. Athyros V.G., Tziomalos K., Karagiannis A., Mikhailidis D.P. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011, 5:24-34.
3. Guyton J.R., Goldberg A.C., Kreisberg R.A., Sprecher D.L., Superko H.R., O'Connor C.M. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737-743.
4. Malik S., Kashyap M.L. Niacin, lipids, and heart disease. Curr Cardiol Rep 2003, 5:470-476.
5. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
6. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl J Med 2001, 345:1583-1592.
7. Ballantyne C.M., Davidson M.H., McKenney J., Keller L.H., Bajorunas D.R., Karas R.H. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008, 101:1428-1436.
8. Sazonov V., Maccubbin D., Sisk C.M., Canner P.L. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 2013, 67:297-302.
9. Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990, 723-726.
10. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA 2000, 1263-1270.
11. Grundy S.M., Vega G.L., McGovern M.E., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 1568-1576.
12. Fazio S., Guyton J.R., Lin J., Tomassini J.E., Shah A., Tershakovec A.M. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metabol 2010, 983-993.
13. Hamilton S.J., Chew G.T., Davis T.M., Watts G.F. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diabetes Vasc Dis Res 2010, 296-299.
14. Sorrentino S.A., Besler C., Rohrer L., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 110-122.
15. Pang J., Chan D.C., Hamilton S.J., Tenneti V.S., Watts G.F., Barrett P.H.R. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014, 34:427-432.
16. Sahebkar A. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc Med 2014, 19:54-66.
17. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
18. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression,. J Am Coll Cardiol 2013, 61:440-446.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
21. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Bodor E.T., Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008, 153(Suppl. 1):S68-S75.
23. Gille A., Bodor E.T., Ahmed K., Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008, 48:79-106.
24. Lamon-Fava S., Diffenderfer M.R., Barrett P.H., et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008, 28:1672-1678.
25. Hernandez C., Molusky M., Li Y., Li S., Lin J.D. Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid. Cell Metab 2010, 12:411-419.
26. National Cholesterol Education Program Expert Panel on Detection E.; treatment of high blood cholesterol in, a. Third report of the national cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in Adults (Adult treatment Panel III) final report. Circulation 2002, 106:3143-3421.
27. Genest J., Frohlich J., Fodor G., McPherson R. Working Group on, H.; Other, D. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ - Can Med Assoc J J de l'Association medicale Can 2003, 169:921-924.
28. Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
29. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C. European Consensus Panel on, H.-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
30. Scanu A.M., Bamba R. Niacin and lipoprotein (a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008, 101:S44-S47.
31. Airan-Javia S.L., Wolf R.L., Wolfe M.L., Tadesse M., Mohler E., Reilly M.P. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy. Am Heart J 2009, 157:687e1-687e8.
32. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther Spons by Int Soc Cardiovasc Pharmacother 2005, 19:403-414.
33. Guyton J.R., Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 2007, 99:22C-31C.
34. Canner P.L., Furberg C.D., McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006, 97:477-479.